|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kirby M, Hirst C and Crawford ED:
Characterising the castration-resistant prostate cancer population:
A systematic review. Int J Clin Pract. 65:1180–1192. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Berthold DR, Pond GR, Soban F, de Wit R,
Eisenberger M and Tannock IF: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer: Updated
survival in the TAX 327 study. J Clin Oncol. 26:242–245. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al; TAX 327 Investigators. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blagosklonny MV: NCI’s provocative
questions on cancer: Some answers to ignite discussion. Oncotarget.
2:1352–1367. 2011.
|
|
6
|
Blagosklonny MV: Why therapeutic response
may not prolong the life of a cancer patient: Selection for
oncogenic resistance. Cell Cycle. 4:1693–1698. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim JJ, Yin B, Christudass CS, Terada N,
Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri
RW, et al: Acquisition of paclitaxel resistance is associated with
a more aggressive and invasive phenotype in prostate cancer. J Cell
Biochem. 114:1286–1293. 2013. View Article : Google Scholar
|
|
8
|
Denzer K, Kleijmeer MJ, Heijnen HF,
Stoorvogel W and Geuze HJ: Exosome: From internal vesicle of the
multivesicular body to intercellular signaling device. J Cell Sci.
113:3365–3374. 2000.PubMed/NCBI
|
|
9
|
Valadi H, Ekström K, Bossios A, Sjöstrand
M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 9:654–659. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vlassov AV, Magdaleno S, Setterquist R and
Conrad R: Exosomes: Current knowledge of their composition,
biological functions, and diagnostic and therapeutic potentials.
Biochim Biophys Acta. 1820:940–948. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshioka Y, Kosaka N, Konishi Y, Ohta H,
Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, et al:
Ultra-sensitive liquid biopsy of circulating extracellular vesicles
using ExoScreen. Nat Commun. 5:35912014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kojima K, Fujita Y, Nozawa Y, Deguchi T
and Ito M: MiR-34a attenuates paclitaxel-resistance of
hormone-refractory prostate cancer PC3 cells through direct and
indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Thery C, Amigorena S, Raposo G and Clayton
A: Isolation and characterization of exosomes from cell culture
supernatants and biological fluids. Curr Protoc Cell Biol. Chapter
3(Unit 3): 222006.
|
|
14
|
Fujita Y, Kojima K, Ohhashi R, Hamada N,
Nozawa Y, Kitamoto A, Sato A, Kondo S, Kojima T, Deguchi T, et al:
MiR-148a attenuates paclitaxel resistance of hormone-refractory,
drug-resistant prostate cancer PC3 cells by regulating MSK1
expression. J Biol Chem. 285:19076–19084. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Marín-Aguilera M, Codony-Servat J, Kalko
SG, Fernández PL, Bermudo R, Buxo E, Ribal MJ, Gascón P and Mellado
B: Identification of docetaxel resistance genes in
castration-resistant prostate cancer. Mol Cancer Ther. 11:329–339.
2012. View Article : Google Scholar
|
|
16
|
Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY
and Chung HC: Identification of genes associated with
chemosensitivity to SAHA/taxane combination treatment in
taxane-resistant breast cancer cells. Breast Cancer Res Treat.
125:55–63. 2011. View Article : Google Scholar
|
|
17
|
Chien AJ and Moasser MM: Cellular
mechanisms of resistance to anthracyclines and taxanes in cancer:
Intrinsic and acquired. Semin Oncol. 35(Suppl 2): S1–S14; quiz S39.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar
|
|
19
|
Ruiz C, Holz DR, Oeggerli M, Schneider S,
Gonzales IM, Kiefer JM, Zellweger T, Bachmann A, Koivisto PA, Helin
HJ, et al: Amplification and overexpression of vinculin are
associated with increased tumour cell proliferation and progression
in advanced prostate cancer. J Pathol. 223:543–552. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cruz-Monserrate Z, Qiu S, Evers BM and
O’Connor KL: Upregulation and redistribution of integrin
alpha6beta4 expression occurs at an early stage in pancreatic
adenocarcinoma progression. Mod Pathol. 20:656–667. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Geisler C, Gaisa NT, Pfister D, Fuessel S,
Kristiansen G, Braunschweig T, Gostek S, Beine B, Diehl HC, Jackson
AM, et al: Identification and validation of potential new
biomarkers for prostate cancer diagnosis and prognosis using
2D-DIGE and MS. BioMed Res Int. 2015:4542562015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kumano M, Miyake H, Abolghait SK, Behnsawy
HM and Fujisawa M: β4-integrin-mediated cytotoxic activity of AexU
in human prostate cancer PC3 cells. Oncol Lett. 6:1482–1486.
2013.PubMed/NCBI
|
|
23
|
Yoshioka T, Otero J, Chen Y, Kim YM,
Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E,
Enomoto K, et al: β4 Integrin signaling induces expansion of
prostate tumor progenitors. J Clin Invest. 123:682–699.
2013.PubMed/NCBI
|
|
24
|
Gleason B, Adley B, Rao MS and Diaz LK:
Immunohistochemical detection of the beta4 integrin subunit in
pancreatic adenocarcinoma. J Histochem Cytochem. 53:799–801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lipscomb EA and Mercurio AM: Mobilization
and activation of a signaling competent alpha6beta4integrin
underlies its contribution to carcinoma progression. Cancer
Metastasis Rev. 24:413–423. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goldmann WH, Auernheimer V, Thievessen I
and Fabry B: Vinculin, cell mechanics and tumour cell invasion.
Cell Biol Int. 37:397–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Srichai M and Zent R: Integrin structure
and function. Cell-Extracellular Matrix Interactions in Cancer.
Zent R and Pozzi A: Springer; New York: pp. 19–41. 2010, View Article : Google Scholar
|
|
28
|
Peng X, Nelson ES, Maiers JL and DeMali
KA: New insights into vinculin function and regulation. Int Rev
Cell Mol Biol. 287:191–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Banyard J, Chung I, Migliozzi M, Phan DT,
Wilson AM, Zetter BR and Bielenberg DR: Identification of genes
regulating migration and invasion using a new model of metastatic
prostate cancer. BMC Cancer. 14:3872014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mizutani K, Terazawa R, Kameyama K, Kato
T, Horie K, Tsuchiya T, Seike K, Ehara H, Fujita Y, Kawakami K, et
al: Isolation of prostate cancer-related exosomes. Anticancer Res.
34:3419–3423. 2014.PubMed/NCBI
|
